The bioprocessing sector, a critical component within the Life Sciences industry, continually faces hurdles in bringing innovative technologies from development to market. BioProcess360 Partners has introduced a novel investment fund aimed at bridging this gap. By providing both capital and
Merck has unveiled its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This state-of-the-art facility is located at the Life Science Center in Nantong. The endeavor is backed by a substantial €6.6 million ($7.1 million) investment and aims to meet the burgeoning d
An exciting development in the biotechnology industry has emerged as 3D Bio-Tissues, a biotech startup supported by BSF Enterprise, has successfully created high-quality lab-grown leather. This remarkable bio-engineered material, which was recently showcased at the Future Fabrics Expo in London,
Synthetic biology, commonly known as synbio, is at the cutting edge of biotechnology, offering revolutionary solutions for various industries. Dr. John Cumbers, a pioneering figure in this field and the Founder and CEO of SynBioBeta LLC, provides profound insights into how synbio can address
The introduction of the BIOSECURE Act marks a significant moment in U.S. legislative history, specifically targeting the intersection of national security and biotechnology. This proposed legislation aims to halt federal contracts with Chinese biotech firms, citing potential national security
The proposed BIOSECURE Act stands poised to significantly alter the landscape of U.S.-China biopharma partnerships by addressing national security concerns through restrictive measures. Specifically, the act aims to block certain Chinese biotech equipment and service providers from the U.S. market.
